Prognostic significance of erythropoietin expression in human endometrial carcinoma

Cancer

Volumn 100, Issue 11, 2004, Pages 2376-2386

  Acs, Geza ^a   Xu, Xiaowei ^a   Chu, Christina ^a   Acs, Peter ^b   Verma, Ajay ^c  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Endometrial neoplasms; Erythropoietin; Erythropoietin receptor; Hypoxia inducible factor

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; ESTROGEN RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROGESTERONE RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER INVASION; CORRELATION ANALYSIS; ENDOMETRIUM CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; CELL HYPOXIA; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; ERYTHROPOIETIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MENSTRUAL CYCLE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, ERYTHROPOIETIN; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TRANSCRIPTION FACTORS;

EID: 2442650576     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20244     Document Type: Article

References (29)

1. Tilbrook PA, Klinken SP. Erythropoietin and erythropoietin receptor. Growth Factors. 1999;17:25-35.
2. Ebert BL, Bunn HF. Regulation of the erythropoietin gene. Blood. 1999;94:1864-1877.
3. Wojchowski DM, Gregory RC, Miller CP, Pandit AK, Pircher TJ. Signal transduction in the erythropoietin receptor system. Exp Cell Res. 1999;253:143-156.
4. Masuda S, Okano M, Yamagishi K, Nagao M, Ueda M, Sasaki R. A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem. 1994;269:19488-19493.
5. Acs G, Acs P, Beckwith SM, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res. 2001;61:3561-3565.
6. Acs G, Zhang PJ, Rebbeck TR, Acs P, Verma A. Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer. 2002;95:969-981.
7. Juul SE, Zhao Y, Dame JB, Du Y, Hutson AD, Christensen RD. Origin and fate of erythropoietin in human milk. Pediatr Res. 2000;48:660-667.
8. Yasuda Y, Masuda S, Chikuma M, Inoue K, Nagao M, Sasaki R. Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J Biol Chem. 1998;273:25381-25387.
9. Yokomizo R, Matsuzaki S, Uehara S, Murakami T, Yaegashi N, Okamura K. Erythropoietin and erythropoietin receptor expression in human endometrium throughout the menstrual cycle. Mol Hum Reprod. 2002;8:441-446.
10. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci U S A. 1990;87:5978-5982.
11. Juul SE, Anderson DK, Li Y, Christensen RD. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res. 1998;43:40-49.
12. Acs G, Zhang PJ, McGrath CM, et al. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol. 2003;162:1789-1806.
13. Yasuda Y, Fujita Y, Masuda S, et al. Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs. Carcinogenesis. 2002;23:1797-1805.
14. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5-26.
15. Ronnett BM, Zaino RJ, Ellenson LH, Kurman RJ. Endometrial carcinoma. In: Kurman RJ, editor. Blaustein's pathology of the female genital tract (5th edition). New York: Springer-Verlag, 2002:501-559.
16. Noyes RW, Hertig AT, Rock J. Dating the endometrial biopsy. Fertil Steril. 1950;1:3-25.
17. [No authors listed]. FIGO stages (announcements)-1988 revision. Gynecol Oncol. 1989;35:125-127.
18. Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG, Wilkinson EJ. Histological typing of female genital tract tumours (2nd edition). New York: Springer-Verlag, 1994.
19. Matsuzaki S, Canis M, Yokomizo R, Yaegashi N, Bruhat MA, Okamura K. Expression of erythropoietin and erythropoietin receptor in peritoneal endometriosis. Hum Reprod. 2003;18:152-156.
20. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989;49:6449-6465.
21. 2 tension measurements. Cancer Res. 1991;51:3316-3322.
22. Lessey BA, Killam AP, Metzger DA, Haney AF, Greene GL, McCarty KS Jr. Immunohistochemical analysis of human uterine estrogen and progesterone receptors throughout the menstrual cycle. J Clin Endocrinol Metab. 1988;67:334-340.
23. Lebovic DI, Shifren JL, Ryan IP, et al. Ovarian steroid and cytokine modulation of human endometrial angiogenesis. Hum Reprod. 2000;15 Suppl 3:67-77.
24. Aebersold DM, Burri P, Beer KT, et al. Expression of hypoxia-inducible factor-1α: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 2001;61:2911-2916.
25. Vaupel P, Kelleher DK, Hockel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol. 2001;28(2 Suppl 8):29-35.
26. Thatcher N. Management of chemotherapy-induced anemia in solid tumors. Semin Oncol. 1998;25(3 Suppl 7):23-26.
27. Yasuda Y, Musha T, Tanaka H, et al. Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice. Br J Cancer. 2001;84:836-843.
28. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 2003;4:459-460.
29. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255-1260.